Article Sidebar
Published:
Jan 10, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension
Abstract
Methods: The medical records of 110 patients treated in North China Electric Power University Hospital, Beijing, China from July 2018 to October 2022 were retrospectively analyzed. Control group (CG; n = 50) was administered oral amlodipine (5 mg daily for 6 months), while the study group (SG; n = 60) received one tablet of co-formulated valsartan (80 mg)) and amlodipine (5 mg) daily for 6 months. All the patients, in addition to the above drugs, were also placed on insulin and atorvastatin calcium. After a 6-month treatment period, the therapeutic effect and incidence of adverse effects were compared between CG and SG. Blood glucose-related indices (glycosylated hemoglobin (HbA1c), 2 h postprandial blood glucose (2 h PG), and fasting blood glucose (FBG)) and blood pressure indices, viz, (diastolic blood pressure (DBP), systolic blood pressure (SBP)) were compared.
Results: Compared to the pre-treatment values, both groups showed significant decrease in 2 h PG, FBG, HbA1c, SBP and DBP after treatment (p < 0.05), but the 2 h PG, FBG, HbA1c, SBP and DBP in SG were significantly lower in comparison to CG (p < 0.05). The overall response rate (ORR) of CG was significantly lower in comparison to SG (p < 0.05). In SG, there was significant reduction in the incidence of adverse effects compared to CG (p < 0.05).
Conclusion: The combination of valsartan and amlodipine is effective in treating T2DM co-morbid with hypertension, and satisfactorily controls blood glucose level and blood pressure with a relatively high level of safety. Further experiments would be required to ascertain the reliability of these findings.
